Curative Biosciences, Inc.
CBDX
$0.0001
$0.000.00%
| 03/31/2018 | 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 700.00% | 6,539.71% | -34.03% | -61.86% | -13.04% |
| Depreciation & Amortization | -- | -- | 0.00% | 0.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 700.00% | 6,539.71% | -31.84% | -60.92% | -24.53% |
| Operating Income | -700.00% | -6,539.71% | 31.84% | 60.92% | 24.53% |
| Income Before Tax | -700.00% | -6,539.71% | 31.84% | 60.92% | 24.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -700.00% | -6,539.71% | 31.84% | 60.92% | 24.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -700.00% | -6,539.71% | 31.84% | 60.92% | 24.53% |
| EBIT | -700.00% | -6,539.71% | 31.84% | 60.92% | 24.53% |
| EBITDA | -854.55% | -7,290.16% | 32.77% | 61.86% | 28.26% |
| EPS Basic | -433.33% | -6,925.00% | 31.25% | 62.07% | 0.00% |
| Normalized Basic EPS | -400.00% | -5,733.33% | 30.00% | 61.11% | 0.00% |
| EPS Diluted | -433.33% | -6,925.00% | 31.25% | 62.07% | 0.00% |
| Normalized Diluted EPS | -400.00% | -5,733.33% | 30.00% | 61.11% | 0.00% |
| Average Basic Shares Outstanding | 24.62% | 2.41% | 0.22% | 0.95% | 0.96% |
| Average Diluted Shares Outstanding | 24.62% | 2.41% | 0.22% | 0.95% | 0.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
